texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Morris D. Groves, M.D.

General Summary

Morris D. Groves, M.D., leads the Texas Oncology–Austin Brain Tumor Center. Dr. Groves develops promising new treatments to help patients fight brain tumors.

Prior to joining Texas Oncology, Dr. Groves served as both a tenured associate professor for the department of neuro-oncology and as associate director in the Brain and Spine Center at The University of Texas MD Anderson Cancer Center in Houston. He has served as principal investigator and co-principal investigator for dozens of important research trials and has held numerous academic appointments during his tenure with The University of Texas MD Anderson Cancer Center. In addition, he has authored numerous research papers and articles on brain cancer.

Education

  • Fellowship (Neuro Oncology)
    The University of Texas MD Anderson Cancer Center, Houston, TX
  • Chief Resident (Neurology)
    UT Health Science Center, Houston, TX
  • Resident (Neurology)
    UT Health Science Center, Houston, TX, 
  • Intern (Transitional Medicine)
    LBJ Hospital, Houston, TX
  • Intern (General Surgery)
    Baylor College of Medicine, Houston, TX
  • Juris Doctor
    South Texas College of Law, Houston, TX
  • Medical Doctorate
    Baylor College of Medicine, Houston, TX 
  • Bachelor of Science
    Baylor University, Waco, TX

Medical Practice

  • Director, Texas Oncology, Austin Brain Tumor Center, Austin, TX 2012-present
  • Medical Director & Chair, Neuro-Oncology Research, US Oncology 2013-present
  • Associate Chair, Developmental Therapeutics, US Oncology Research 2013-present
  • Associate Clinic Director for the Brain and Spine Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-2012
  • Associate Professor (with tenure), Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-2012
  • Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX, 2000-2006
  • Director, Inpatient Services, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-2007

Research Interest

Recent Research Protocols

  • Local Principal Investigator, BTTC 11-02 - Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma, Genentech.
  • Local Principal Investigator, An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma, Celldex.
  • Local Principal Investigator A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma, Celldex.
  • Local Principal Investigator. Phase II Double-Blinded Placebo-controlled Study of Bevacizumab with or without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma. RTOG 1122
  • Local Principal Investigator. Phase II Trial of Concurrent RAD001(Everolimus) with Temozolomide/Radiation Followed by Ajuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma. RTOG 0913.
  • Lead Principal Investigator, BTTC12-01 – A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab. GSK
  • Lead Principal Investigator, Determination of Cerebrospinal Fluid Levels of Glycolipids as a Predictor of Malignant Meningitis, TO-1622
  • Lead Principal Investigator, Neoplastic Meningitis in Community Oncology Practice, TO-1626
  • Local Principle Investigator, A phase II and pharmacokinetic study of intrathecal trastuzumab in patients with HER2 overexpressing cancers with metastases to the leptomeninges, Sponsor Northwestern University, Genentech.
  • Co-Principle Investogator, A phase II study of Capecitabine plus BKM-120 in breast cancer patients with brain metastases, Sponsor Novartis.
  • Principle Investigator, Phase II study of aldoxrubicin in recurrent glioblastoma, CyTrx Sponsor
  • Local Principle Investigator, Indoximod with or without temozolomide and SRS in recurrent high grade glioma, NewLink Genetics Sponsor.
  • US Oncology Network Lead Principle Investigator, A phase I study of DSP-7888 in recurrent solid tumors, Sponsor: Boston Biomedical, Inc.
  • US Oncology Network Lead Principle Investigator, A randomized phase II study of bevacizumab +/- DSP-7888 in recurrent glioblastoma, Sponsor: Boston Biomedical, Inc.
  • Local Principle Investigator, A phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety or Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy, Sponsor Orbus Therapeutics, Inc.
  • Local Principle Investigator, A Phase II, Multi-center, Open-label Study of Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA) for Recurrent Glioblastoma or Gliosarcoma, 2017-ongoing, Sponsor DNAtrix Therapeutics.

Surgery Locations

Other Information

Accolades & Memberships

Awards

  • Outstanding Teacher in Neurology, UTHSCH, 1994
  • Chief Resident—Department of Neurology, UTHSCH, 1995-1996
  • Outstanding Teacher in Neurology, UTHSCH, 1996
  • The Gullikson Foundation Award for Quality of Life Research, 2000
  • Best Doctors in America, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018
  • Texas Super Doctors, 2011, 2012, 2013, 2014, 2015, 2016, 2017
  • Texas Monthly Top Doctors, 2015
Memberships
  • State Bar of Texas, Member, 1992-present
  • Society for Neuro Oncology, Member, 1996-present

Community Service

Publications

  • Leptomeningeal Metastases: A RANO Proposal for Response Criteria

    Neuro-Oncology, 2017

  • Leptomeningeal metastases presenting exclusively with ocular disturbance in 34 patients: A tertiary care cancer hospital experience

    Journal of Clinical Neuroscience, 2017

  • Most common sites on MRI of intracranial neoplastic leptomeningeal disease

    Journal of Clinical Neuroscience, 2017

  • Association between 18F-FDG PET/CT and MRI appearance of spinal leptomeningeal disease before and after treatment at a tertiary referral center

    Journal of Solid Tumors, 2016

  • Brain Tumor Trials Collaborative. A Phase II study of Bevacizumab and Erlotinib after Radiation and Temozolomide in MGMT unmethylated GBM patients

    Journal of Neuro-Oncology, 2016

Show all Publications
  • Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma

    Neuro-Oncology, 2015

  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

    Neuro-Oncology, 2015

  • Phase I/II Study of Erlotinib and Temsirolimus for Patients with Recurrent Malignant Glioma: North American Brain Tumor Consortium Trial 04-02

    Neuro-Oncology, 2014

  • A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

    Clinical Cancer Research, 2013

  • Leptomeningeal metastases from genitourinary cancer: The University of Texas MD Anderson Cancer Center experience

    Medical Oncology, 2013

  • Phase I study of GRN1005 in recurrent malignant glioma

    Clinical Cancer Research, 2013

  • Phase I/Ib Study of Lonafarnib and Temozolomide in Patients with Recurrent or Temozolomide Refractory Glioblastoma

    Cancer, 2013

  • The identification and characterization of breast cancer CTCs competent for brain metastasis

    Science Translational Medicine, 2013

  • Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis

    Journal of Neuro-Oncology, 2013

  • Bevacizumab use in disseminated choroid plexus papilloma

    Journal of Neuro-Oncology, 2013

  • Case Studies of Patients Receiving Intraventricular Topotecan for Treatment of Neoplastic Meningitis

    Journal of Advanced Practice in Oncology, 2012

  • Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients with Advanced Solid Tumors

    Journal of Clinical Oncology, 2012

  • Helping Patients Make the Best Decision Regarding Duration of Temozolomide Chemotherapy Treatment

    Continuum: Lifelong Learning in Neurology, 2012

  • Advances in Understanding and Treatment of Glioblastoma Multiforme

    Advances in Neurosciences, 2012

  • Intraventricular and Intrathecal Therapy

    The Chemotherapy Source Book, 2012

  • Neurologic Complications Associated with Biologic Agents

    Neurologic Complications of Cancer Therapy, 2012

  • Advanced Therapy of Breast Disease

    Management of Central Nervous System Metastases in Breast Cancer, 2011

  • Leptomeningeal Disease

    Neurosurgery Clinics of North America, 2011

  • High-Grade Gliomas

    Current Treatment Options in Neurology, 2011

  • Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma

    Cancer, 2011

  • Biology and Therapy of Neoplastic Meningitis

    Current Oncology Reports, 2010

  • Known and Emerging Biomarkers of Leptomeningeal Metastasis and Its Response to Treatment

    Future Oncology, 2010

  • New Strategies in the Management of Leptomeningeal Metastases

    Archives of neurology, 2010

  • A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma

    Neuro-Oncology, 2010

  • Tonsillar Pseudotumor: Complications of Chronically-administered Temozolomide

    Journal of Neuro-Oncology, 2010

  • Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma

    Journal of Neuro-Oncology, 2010

  • A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor

    Journal of Neuro-Oncology, 2010

  • Comparative Risk of Leptomeningeal Dissemination of Cancer after Surgery or Stereotactic Radiosurgery for Supratentorial Solid Tumor Metastases

    Neurosurgery, 2009

  • Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment

    Seminars in Oncology, 2009

  • Two Phase II Trials of Temozolomide with Interferon-a2b (Pegylated and non-pegylated) in Patients with Recurrent Glioblastoma Multiforme

    British Journal of Cancer, 2009

  • Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma

    Journal of Neuro-Oncology, 2009

  • Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa

    Journal of Neurosurgery, 2008

  • Phase II Trial of Irinotecan and Thalidomide in Adults with Recurrent Glioblastoma Multiforme

    Neuro-Oncology, 2008

  • Low Grade Astrocytoma Presenting with Visual Loss

    Journal of Neuro-Oncology, 2008

  • Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

    Journal of Neuro-Oncology, 2008

  • Prognostic Factors and Outcomes in Patients with Leptomeningeal Melanomatosis

    Neuro-Oncology, 2008

  • Leptomeningeal Metastases: Still a Challenge

    American Society of Clinical Oncology Meeting, 2008

  • A Multicenter Phase II Trial of Intrathecal Topotecan in Patients with Meningeal Malignancies

    Neuro-Oncology, 2008

  • Intraventricular and Intrathecal Therapy

    The Chemotherapy Source Book, 2008

  • Neoplastic Meningitis

    Tumors of the Brain and Spine, 2007

  • Tumors of the Spinal Cord & Intradural Space

    Tumors of the Brain and Spine, 2007

  • A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

    Journal of Neuro-Oncology, 2007

  • Proteomic Identification of Biomarkers in the Cerebrospinal Fluid (CSF) of Astrocytoma

    Journal of Proteome Research, 2007

  • Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma

    International Journal of Oncology, 2006

  • Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study

    Clinical Cancer Research, 2006

  • Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study

    Journal of Clinical Oncology, 2006

  • Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status

    Journal of Neuro-Oncology, 2006

  • Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710

    International Journal of Radiation Oncology, Biology, Physics, 2006

  • Combination celecoxib and temozolomide in C6 rat glioma orthotopic model

    Oncology Reports, 2006

  • Phase I Study of Capecitabine in Combination with Temozolomide in the Treatment of Patients with Brain Metastases From Breast Carcinoma

    Cancer, 2006

  • Neurological Complicatons of Head and Neck Cancer

    Neurological Complications of Systemic Cancer, 2006

  • Systemic and Intrathecal Chemotherapy for Tumors of the Spine, Spinal Cord and Peripheral Nerves

    Spinal Cord and Spinal Cord Tumors,Principles and Practices, 2006

  • Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract

    Cancer, 2005

  • The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors

    Cancer, 2005

  • Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme

    Journal of Neuro-Oncology, 2005

  • Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: A North American brain tumor consortium study

    Journal of Clinical Oncology, 2005

  • Glutathione S-transferase polymorphisms and survival in primary malignant glioma

    Clinical Cancer Research, 2004

  • 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme

    Neuro-Oncology, 2004

  • Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study

    Journal of Clinical Oncology, 2004

  • Leptomeningeal Carcinomatosis: Diagnosis and Management

    Intracranial Metastases, Current Management Strategies, 2004

  • Management of Central Nervous System Metastases in Breast Cancer

    Advanced Therapy of Breast Disease, 2004

  • Epidemiology and Pathophysiology in Neuro Oncology

    Saunders Manual of Neurologic Practice, 2003

  • Meningeal and Spinal Metastases

    Saunders Manual of Neurologic Practice, 2003

  • Metastatic Brain Tumors

    Saunders Manual of Neurologic Practice, 2003

  • Metastatic Tumors

    Atlas of Cancer, 2003

  • Spinal Cord Tumors

    Saunders Manual of Neurologic Practice, 2003

  • Clinical Presentations

    Saunders Manual of Neurologic Practice, 2003

  • The Pathogenesis of Neoplastic Meningitis

    Current Oncology Reports, 2003

  • Response of neoplastic meningitis from solid tumors to oral capecitabine

    Journal of Neuro-Oncology, 2003

  • Paraneoplastic chorea: case study with autopsy confirmation

    Neuro-Oncology, 2002

  • Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

    Journal of Clinical Oncology, 2002

  • Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU

    Int J Oncol, 2001

  • Peripheral nerve injury after brief lithotomy for transurethral collagen injection

    Urology, 2000

  • Neoplasms

    Prognosis in Neurological Disorders, 2000

  • Radicular pain can be a symptom of elevated intracranial pressure

    Neurology, 1999

  • A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

    Int J Radiat Oncol Biol Phys, 1999

  • Papillary carcinoma of the thyroid: additional evidence in support of a familial component

    Cancer Invest, 1989